会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Inclusion complexes of racemic ibuproxam and of optically active
ibuproxam with cyclodextrin derivatives, pharmaceutical preparations
containing said inclusion complexes and methods for using same
    • 外消旋布洛康和旋光布洛克星与环糊精衍生物的包合物,含有所述包合物的药物制剂及其使用方法
    • US5840714A
    • 1998-11-24
    • US602729
    • 1996-02-20
    • Janko ZmitekKatarina VerhnjakDarja Fercej-TemeljotovMateja Kovacic Anton Lavric Breda Bole-Vunduk
    • Janko ZmitekKatarina VerhnjakDarja Fercej-TemeljotovMateja Kovacic Anton Lavric Breda Bole-Vunduk
    • A61K9/00A61K31/165A61K47/48C07C51/00C07C57/00C07C259/06A61K47/40C07H21/00
    • B82Y5/00A61K31/165A61K47/48969C07C259/06Y10S514/965
    • Inclusion Complexes of Racemic Ibuproxam and of Optically Active Ibuproxam with Cyclodextrin Derivatives, Process for the Preparation Thereof, Pharmaceutical Preparations Containing these Inclusion Complexes or Containing Optically Active S-(+)-Ibuproxam, and Use Thereof There are disclosed novel inclusion complexes of racemic ibuproxam and of optically active S-(+)-ibuproxam with hydrophilic and hydrophobic cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, also with .beta.-cyclodextrin alone. Further a process for preparing S-(+)-ibuproxam and inclusion complexes of racemic ibuproxam and of optically active S-(+)-ibuproxam with hydrophilic and hydrophobic derivatives of .beta.-cyclodextrin and, in the case of optically active S-(+)-ibuproxam, also with .beta.-cyclodextrin alone, is disclosed. Disclosed are also pharmaceutical compositions containing these inclusion complexes or optically active S-(+)-ibuproxam. Optically active S-(+)-ibuproxam and novel inclusion complexes of racemic ibuproxam and of optically active ibuproxam with cyclodextrin derivatives and, in the case of optically active S-(+)-ibuproxam, also with .beta.-cyclodextrin alone, are better soluble in water and have improved biopharmaceutical properties such as lesser toxicity, better antiinflammatory action and non-irritation of the gastric mucous membrane.
    • PCT No.PCT / SI94 / 00015 Sec。 371日期1996年2月20日 102(e)日期1996年2月20日PCT 1994年9月6日PCT PCT。 第WO95 / 07076号公报 日期1995年3月16日包含外消旋布洛康和光学活性布洛克星与环糊精衍生物的复合物,其制备方法,含有这些包合配合物或含有光学活性的S - (+) - 布洛克星姆的药物制剂及其用途已经公开了新颖的 外消旋布洛克星和光学活性的S - (+) - 布洛克星与亲水和疏水性环糊精衍生物的包合物,以及在光学活性的S - (+) - 布洛克星)的情况下,也仅与β-环糊精一起使用。 此外,制备S - (+) - 布洛克星和外消旋布洛克星与光学活性S - (+) - 布洛克星与β-环糊精的亲水和疏水衍生物的包合物的方法,在光学活性S - (+ ) - 吡罗昔康,也是单独使用β-环糊精。 还公开了含有这些包合物或光学活性的S - (+) - 布洛康的药物组合物。 光学活性的S - (+) - 布洛克星和外消旋布洛克星与光学活性布洛克星与环糊精衍生物的新型包合物,以及光学活性的S - (+) - 布洛克星,单独使用β-环糊精的情况较好 并具有改善的生物药物性质,如毒性较小,抗炎作用更好,胃粘膜无刺激性。